2Jemal A,Tiwari RC,Murray T,et al. Cancer statistics, 2004 [J]. Ca Cancer J Clin,2004,54(1): 8-29.
3International Agency for Research on Cancer. GLOBO- CAN 2008[EB/OL]. http://www-dep.iarc.fr.
4Tewari D,Monk BJ,Hunter M,et al.Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J].Invest New Drugs,2004,4:475-480.
5Ferrandina G,Paris I,Ludovisi M,et al.Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer:updated results and long-term survival[J].Gynecol Oncol,2005,98(2):267-273.
6Spriggs D.Optimal sequencing in the treatment of recurrent ovarian cancer[J].Gynecol Oncol,2003,90(Suppl):39-44.
7du Bois A,Quinn M,Thigpen T,et al.2004 consensus statements on the management of ovarian cancer:final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC2004)[J].Ann Oncol,2005,16 (Suppl 8):viii7-viii12.
8Rustin FJS,Bast RC,Kelloff GJ,et al.Use of CA125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer[J].Clin Cancer Res,2004,10:3919-3926.
9Harries M,Gore M.Part Ⅱ:chemotherapy for epithelial ovarian cancer-treatment of recurrent disease[J].Lancet Oncol,2002,3:537-545.
10Penson RT,Dignan F,Seiden MV.et al.Attitudes to chemotherapy in patients with ovarian cancer[J].Gynecol Oncol,2004,94:427-435.
